Aptagen, LLC
F5R1 (ID# 8218)
![](https://www.aptagen.com/wp-content/uploads/F5R1.jpg)
DNA
alpha-synuclein
Protein
2.40 nM (reported value)
10 mM Tris-HCI, 1 mM EDTA, 2 M NaCI, pH 7.5
25°C
NA If the oligo is a known aptamer sequence: For binding studies, perform a refolding protocol to ensure proper function (i.e. binding to antigen or target). Refer to the aptamer reference source for the appropriate refolding parameters and binding conditions. Note: it is unknown whether aptamer functions properly without refolding.
Researchers mention that the designed aptamers provided good specificity to alpha-synuclein.
N/A
5'-dApdTpdCpdGpdApdGpdTpdGpdTpdGpdTpdApdCpdGpdGpdGpdGpdTpdCpdCpdGpdGpdTpdApdGpdGpdGpdTpdGpdGpdCpdGpdApdGpdGpdTpdCpdTpdTpdCpdCpdTpdGpdTpdCpdGpdTpdApdGpdCpdApdGpdGpdApdTpdCpdCpdAp-3'
![](/wp-content/uploads/apta-sequence-abbr.png)
58
18136.69
Note: Information on this aptamer oligo was obtained from the literature and hasn't been validated by Aptagen.
Yuan Zheng, Jing Qu, Fenqin Xue, Yan Zheng, Bo Yang, Yongchang Chang, Hui Yang, Jianliang Zhang, Novel DNA Aptamers for Parkinson’s Disease Treatment Inhibit α-Synuclein Aggregation and Facilitate its Degradation, Molecular Therapy - Nucleic Acids, Volume 11, 2018, Pages 228-242, ISSN 2162-2531
Have your aptamer oligo synthesized ORDER
We are always looking for ways to improve. Please tell us what you think.